# Parabilis Medicines, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Parabilis Medicines, Inc.). ## Overview Parabilis Medicines, Inc. is a U.S.-based clinical-stage biopharmaceutical company developing medicines against disease-driving protein targets that have historically been difficult to address with conventional drugs. Its proprietary Helicons platform uses stabilized helical peptides, with programs including zolucatetide for rare solid tumors and research aimed at severe rare genetic diseases. ## Products & services • Helicons stabilized helical peptide platform • Zolucatetide for desmoid tumors • Zolucatetide expansion opportunities in FAP and HCC • Rare genetic disease drug discovery programs • Partnered research and licensing programs - **Collaboration research services** (100%) — Research activities conducted for partners under license and collaboration agreements. - **Zolucatetide development** (0%) — Clinical development of zolucatetide for desmoid tumors and other rare solid tumors. - **Helicons platform** (0%) — Proprietary stabilized peptide technology for binding and modulating difficult protein targets. - **Rare genetic disease programs** (0%) — Discovery and development activities targeting severe rare genetic diseases. - Helicons stabilized helical peptide platform - Zolucatetide for desmoid tumors - Zolucatetide opportunities in FAP and HCC - Rare genetic disease drug discovery programs - Partnered research and licensing programs ## Customers Parabilis currently operates primarily as a development-stage biotechnology company rather than a commercial pharmaceutical supplier, and it has not generated product revenue. Its principal commercial counterparties are biopharmaceutical collaborators such as Regeneron, which may fund research, license technology, or support future development. Future customers could include healthcare providers, specialty pharmacies, and patients whose treatments receive regulatory approval and reimbursement. - **Strategic biopharmaceutical partners** (primary) — Companies seeking access to Helicons technology, discovery programs, or partnered research capabilities. - **Regeneron collaboration** (primary) — Current partner funding research on collaboration targets under the Regeneron Agreement. - **Oncology providers** (secondary) — Specialist physicians and treatment centers that could administer approved zolucatetide therapies. - **Rare-disease healthcare channels** (emerging) — Specialty pharmacies, payors, and providers supporting future genetic-disease treatments. - Regeneron funds and collaborates on selected research targets - Future biopharma partners may license programs or platform rights - Oncology specialists may use approved zolucatetide treatments - Specialty pharmacies could distribute future rare-disease medicines - Government and private payors determine treatment access and reimbursement ## Geography Parabilis is headquartered and incorporated in the United States, where its corporate, research, clinical-development, and public-company activities are centered. Its development model relies on external contract research and manufacturing organizations, clinical sites, and potential commercial partners that may operate across multiple countries. The reported excerpts do not provide country-level revenue or a regional revenue distribution, and the company has not generated product sales. - United States is the company’s disclosed home market - Clinical development may involve multinational trial sites - Contract research and manufacturing can create cross-border exposure - Future commercialization may require international partners - No country-level revenue is disclosed in the excerpts ## Strategy Parabilis is prioritizing clinical development of zolucatetide and evaluation of additional indications, including FAP, HCC, and other rare solid tumors. It is also advancing the Helicons platform and rare genetic disease research while using collaborations such as the Regeneron Agreement to extend research capabilities and funding. Future commercialization will depend on regulatory approvals, manufacturing readiness, reimbursement, and either internal sales capabilities or third-party distribution partnerships. - **Advance zolucatetide clinical development** (short-term) — Clinical validation is required before the lead program can produce product revenue. - **Expand potential zolucatetide indications** (medium-term) — Additional rare-disease indications could increase the addressable market if supported by clinical data. - **Develop the Helicons platform** (long-term) — The platform is intended to address protein targets beyond the reach of conventional medicines. - **Use strategic collaborations** (medium-term) — Partners can provide research funding, development capabilities, and future commercialization support. - Advance zolucatetide through clinical development in desmoid tumors - Evaluate FAP, HCC, and other rare solid-tumor indications - Build Helicons applications against difficult protein targets - Develop treatments for severe rare genetic diseases - Use collaborations to fund research and expand capabilities - Establish future sales and distribution infrastructure ## Risks Parabilis faces the core risks of clinical-stage biotechnology: candidates may fail to demonstrate efficacy or safety, obtain regulatory approval, secure reimbursement, or achieve commercial adoption. Its dependence on external manufacturers, research providers, collaborators, and future sales partners creates execution and control risks, while competition from better-funded companies may delay or reduce market access. The company also has no approved products and must continue funding substantial research, clinical, regulatory, and commercialization activities before product revenue can become meaningful. - **Clinical development failure** [critical] — Trials may fail to show adequate efficacy or acceptable safety, preventing approval and product revenue. - **Regulatory and reimbursement uncertainty** [high] — FDA approval, payer coverage, discounts, and reimbursement levels determine whether future products can be commercialized. - **Manufacturing and supply-chain execution** [high] — Contract manufacturing defects, capacity constraints, raw-material failures, or cold-chain problems could interrupt clinical supply. - **Dependence on collaborators and commercialization partners** [high] — Partners may not provide sufficient resources or may be unavailable on favorable terms, limiting development and sales execution. - **Competitive pressure** [high] — Larger pharmaceutical and biotechnology companies may have greater capital, technology, regulatory experience, and commercial reach. - **Capital requirements** [high] — The company has no commercial product base and must fund research, trials, regulatory work, manufacturing, and infrastructure. - Clinical candidates may fail on efficacy, safety, or trial execution - Regulatory approval and reimbursement are uncertain - External manufacturers may face process or supply failures - Cold-chain handling could damage or delay product supply - Larger competitors may reach markets faster - Future operations require substantial additional capital ## Accounting Parabilis recognizes collaboration arrangements under ASC 606 by identifying performance obligations, estimating transaction consideration, allocating that consideration, and recognizing revenue as obligations are satisfied. Revenue under the Regeneron Agreement is recognized over time as research activities are performed, based on costs incurred relative to estimated total costs, making reported revenue sensitive to project progress and cost estimates. Investors should also monitor fair-value changes on financing instruments, research expense accruals, stock-based compensation, and estimates related to clinical and manufacturing commitments. - **Collaboration revenue recognition** — Quarterly revenue may differ from collaboration cash inflows. - **Cost-to-cost progress estimates** — Changes in forecast costs can accelerate or defer reported revenue. - **Milestone and royalty consideration** — Future revenue timing may be volatile and dependent on clinical and regulatory outcomes. - **Research and development accruals** — Accrual revisions can affect reported operating expenses and net loss. - **Fair-value measurement of financing instruments** — Net income can fluctuate independently of operating performance. - ASC 606 governs license and collaboration revenue recognition - Regeneron research revenue is recognized over time - Revenue depends on incurred versus estimated total costs - Milestone payments require variable-consideration assessment - Research expense accruals depend on vendor estimates - Financing instruments may create fair-value volatility --- *Last updated: 2026-09-24T11:51:52.381167+00:00*